Literature DB >> 21316923

Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Matcheri S Keshavan1, Henry A Nasrallah, Rajiv Tandon.   

Abstract

The current construct of schizophrenia as a unitary disease is far from satisfactory, and is in need of reconceptualization. The first five papers in our "facts" series reviewed what is known about schizophrenia to date, and a limited number of key facts appear to stand out. Schizophrenia is characterized by persistent cognitive deficits, positive and negative symptoms typically beginning in youth, substantive heritability, and brain structural, functional and neurochemical alterations including dopaminergic dysregulation. Several pathophysiological models have been proposed with differing interpretations of the illness, like the fabled six blind Indian men groping different parts of an elephant coming up with different conclusions. However, accumulating knowledge is integrating the several extant models of schizophrenia etiopathogenesis into unifying constructs; we discuss an example, involving a neurodevelopmental imbalance in excitatory/inhibitory neural systems leading to impaired neural plasticity. This imbalance, which may be proximal to clinical manifestations, could result from a variety of genetic, epigenetic and environmental causes, as well as pathophysiological processes such as inflammation and oxidative stress. Such efforts to "connect the dots" (and visualizing the elephant) are still limited by the substantial clinical, pathological, and etiological heterogeneity of schizophrenia and its blurred boundaries with several other psychiatric disorders leading to a "fuzzy cluster" of overlapping syndromes, thereby reducing the content, discriminant and predictive validity of a unitary construct of this illness. The way ahead involves several key directions: a) choosing valid phenotype definitions increasingly derived from translational neuroscience; b) addressing clinical heterogeneity by a cross-diagnostic dimensional and a staging approach to psychopathology; c) addressing pathophysiological heterogeneity by elucidating independent families of "extended" intermediate phenotypes and pathophysiological processes (e.g. altered excitatory/inhibitory, salience or executive circuitries, oxidative stress systems) that traverse structural, functional, neurochemical and molecular domains; d) resolving etiologic heterogeneity by mapping genomic and environmental factors and their interactions to syndromal and specific pathophysiological signatures; e) separating causal factors from consequences and compensatory phenomena; and f) formulating or reformulating hypotheses that can be refuted/tested, perhaps in the mouse or other experimental models. These steps will likely lead to the current entity of schizophrenia being usefully deconstructed and reconfigured into phenotypically overlapping, but etiopathologically unique and empirically testable component entities (similar to mental retardation, epilepsy or cancer syndromes). The mouse may be the way to rescue the trapped elephant!
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21316923      PMCID: PMC3391657          DOI: 10.1016/j.schres.2011.01.011

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  146 in total

1.  Renaming schizophrenia: a Japanese perspective.

Authors:  Mitsumoto Sato
Journal:  World Psychiatry       Date:  2006-02       Impact factor: 49.548

Review 2.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

Review 3.  Dopaminergic mechanisms in idiopathic and drug-induced psychoses.

Authors:  J A Lieberman; B J Kinon; A D Loebel
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

Review 4.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

5.  Rare chromosomal deletions and duplications increase risk of schizophrenia.

Authors: 
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

Review 6.  Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia.

Authors:  R Tandon; J F Greden
Journal:  Arch Gen Psychiatry       Date:  1989-08

7.  'Filtering' and the cognitive deficit in schizophrenia.

Authors:  D R Hemsley; S L Zawada
Journal:  Br J Psychiatry       Date:  1976-05       Impact factor: 9.319

Review 8.  Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology.

Authors:  Rajiv Tandon; Matcheri S Keshavan; Henry A Nasrallah
Journal:  Schizophr Res       Date:  2008-06-02       Impact factor: 4.939

Review 9.  Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.

Authors:  James M Stone; Paul D Morrison; Lyn S Pilowsky
Journal:  J Psychopharmacol       Date:  2007-01-26       Impact factor: 4.153

10.  Large recurrent microdeletions associated with schizophrenia.

Authors:  Hreinn Stefansson; Dan Rujescu; Sven Cichon; Olli P H Pietiläinen; Andres Ingason; Stacy Steinberg; Ragnheidur Fossdal; Engilbert Sigurdsson; Thordur Sigmundsson; Jacobine E Buizer-Voskamp; Thomas Hansen; Klaus D Jakobsen; Pierandrea Muglia; Clyde Francks; Paul M Matthews; Arnaldur Gylfason; Bjarni V Halldorsson; Daniel Gudbjartsson; Thorgeir E Thorgeirsson; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Aslaug Jonasdottir; Asgeir Bjornsson; Sigurborg Mattiasdottir; Thorarinn Blondal; Magnus Haraldsson; Brynja B Magnusdottir; Ina Giegling; Hans-Jürgen Möller; Annette Hartmann; Kevin V Shianna; Dongliang Ge; Anna C Need; Caroline Crombie; Gillian Fraser; Nicholas Walker; Jouko Lonnqvist; Jaana Suvisaari; Annamarie Tuulio-Henriksson; Tiina Paunio; Timi Toulopoulou; Elvira Bramon; Marta Di Forti; Robin Murray; Mirella Ruggeri; Evangelos Vassos; Sarah Tosato; Muriel Walshe; Tao Li; Catalina Vasilescu; Thomas W Mühleisen; August G Wang; Henrik Ullum; Srdjan Djurovic; Ingrid Melle; Jes Olesen; Lambertus A Kiemeney; Barbara Franke; Chiara Sabatti; Nelson B Freimer; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Ole A Andreassen; Roel A Ophoff; Alexander Georgi; Marcella Rietschel; Thomas Werge; Hannes Petursson; David B Goldstein; Markus M Nöthen; Leena Peltonen; David A Collier; David St Clair; Kari Stefansson
Journal:  Nature       Date:  2008-09-11       Impact factor: 49.962

View more
  49 in total

1.  [Neuroimaging markers: their role for differential diagnosis and therapeutic decisions in personalized psychiatry].

Authors:  O Gruber
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

2.  14-3-3 proteins in neurological disorders.

Authors:  Molly Foote; Yi Zhou
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

3.  Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment.

Authors:  Elsa Gilbert; Chantal Mérette; Valérie Jomphe; Claudia Emond; Nancie Rouleau; Roch-Hugo Bouchard; Marc-André Roy; Thomas Paccalet; Michel Maziade
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-31       Impact factor: 5.270

4.  Biomarkers in schizophrenia: we need to rebuild the Titanic.

Authors:  Matcheri S Keshavan; Roscoe Brady
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

Review 5.  Schizotypy: looking back and moving forward.

Authors:  Thomas R Kwapil; Neus Barrantes-Vidal
Journal:  Schizophr Bull       Date:  2014-12-29       Impact factor: 9.306

6.  From Perception to Thought: A Phenomenological Approach to Hallucinatory Experience.

Authors:  Andrea Raballo
Journal:  Schizophr Bull       Date:  2016-11-21       Impact factor: 9.306

7.  The debate about renaming schizophrenia: a new name would not resolve the stigma.

Authors:  W Gaebel; A Kerst
Journal:  Epidemiol Psychiatr Sci       Date:  2018-09-11       Impact factor: 6.892

8.  Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Authors:  Kai Macdonald; David Feifel
Journal:  Acta Neuropsychiatr       Date:  2011-12-19       Impact factor: 3.403

9.  Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia.

Authors:  Matthew W Rice; Rosalinda C Roberts; Miguel Melendez-Ferro; Emma Perez-Costas
Journal:  Brain Struct Funct       Date:  2014-10-01       Impact factor: 3.270

Review 10.  Brain circuit dysfunction in a distinct subset of chronic psychotic patients.

Authors:  Morris B Goldman
Journal:  Schizophr Res       Date:  2014-07-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.